Taken individually, each is a positive headline. Taken together, they point to a sector moving from cautious optimism into genuine, well-funded delivery. The question for science companies, pharmaceutical manufacturers, and growing biotechs is whether their facilities are ready to keep pace.

The Golden Triangle is finding its momentum

Knight Frank's Q1 2026 data confirms what many in the sector have been sensing on the ground. UK life sciences leasing across the Golden Triangle is up 6% year-on-year, with £753.7 million raised across 136 VC deals in the same period. Cambridge led leasing activity across the quarter. There is currently 85,600 sq ft of lab space under offer in London alone.

For a sector that spent much of the past two years recalibrating, managing tighter capital, restructuring at larger occupiers, and navigating an uncertain macro environment, these are encouraging numbers. The pipeline is moving again.

The infrastructure backdrop helps explain some of that renewed confidence. Earlier this year, Cambridgeshire County Council confirmed a land deal representing up to £3 billion of private investment in the next two phases of the Cambridge Biomedical Campus (Europe's largest biomedical research site). The ambition: to nearly double its size over the coming decades, delivering up to 2.4 million sq ft of new life science research, development and innovation space.

In south London, the London Cancer Hub received planning consent for a £1 billion expansion delivering around one million square feet of new research and lab space, and creating 3,000 high-skilled jobs. Together, these are long-term commitments, from developers, investors and local government, to the UK as a serious, durable place to do science.

What this means for lab design and construction

More space under construction is good news. But volume and quality are not the same thing.

The Golden Triangle leasing data is clear that occupiers are increasingly selective. Fully fitted, immediately operational lab space is commanding demand, the Q1 data shows 100% of London deals were for fitted space, reflecting occupiers' desire to minimise fit-out time and capital expenditure.

That preference signals something important: science companies are looking for facilities that work from day one. Not spaces that need months of adaptation before the science can start.

At Inuti, we have been delivering laboratory design and construction across Cambridge, London and Oxford for over 60 years. Our integrated approach, where architecture, MEP engineering and construction move together from the outset rather than in sequence, is what allows us to deliver facilities that are operationally ready on handover, not works-in-progress.

Case study: Co-Labs, Cambridge - a multi-tenant innovation hub designed to give growing science companies fully fitted, immediately usable lab and office space, without the capital commitment of a standalone fit-out.

Case study: First Step by Journey, Cambridge - an early-stage science incubator designed from the ground up for companies at the very beginning of their facility journey.

The UK's pharmaceutical manufacturing ambition is becoming reality

The UK's Life Sciences Innovative Manufacturing Fund (LSIMF) has catalysed £600 million of total investment, public and private, in the first four months of 2026, with a target of £1 billion by summer.

New GMP facilities. Expanded biomanufacturing capacity. Spray-drying infrastructure. A near-patient biomanufacturing facility in Birmingham including three cleanrooms for medicines, vaccines, and advanced cell and gene therapies. The commitment to building serious domestic manufacturing capability is real, and it is moving quickly.

Independent evaluation by Ipsos confirms the fund's leverage effect: every £1 of public grant has unlocked £12 of private investment. That ratio is significant. It means the government's capital commitment is functioning as a catalyst, not a subsidy, pulling in the kind of sustained private investment that builds lasting industrial capacity.

Delivering GMP facilities that are built to be compliant from the start

Pharmaceutical manufacturing facilities are among the most complex built environments in any sector. GMP compliance runs through every design decision, from HVAC systems and cleanroom classification to drainage flows, pressure cascades, and materials of construction. Getting these right from the outset is not optional. Regulatory validation depends on it, and the cost of retrofitting non-compliance is significant.

The facilities that deliver on time and on budget in this environment are almost always the ones where the engineering is in the room from the very first conversation, not brought in after the architectural concept is set.

At Inuti, our GMP facility design and pharmaceutical construction practice works across the full range of regulated manufacturing environments: cGMP suites, cleanrooms from ISO 5 to ISO 8, fill-finish environments, biomanufacturing facilities, and spray-drying infrastructure. Our team brings the regulatory understanding into the design process, so compliance is built in rather than bolted on.

Case study: cGMP Fill-Finish Facility - a bespoke cGMP fill-finish environment delivered ahead of schedule and on budget. The client's words: "Inuti's joined-up approach and deep understanding of the MEP engineering was a real benefit to us."

Case study: Eurofins - laboratory design and build for one of the world's leading testing, inspection and certification companies, requiring careful coordination of complex MEP requirements across specialist environments.

AI is becoming infrastructure - and that changes what facilities need to do

Three investments from the first half of 2026 illustrate where biopharma's relationship with artificial intelligence is heading.

Eli Lilly and Company launched LillyPod earlier this year, a powerful AI supercomputer built in partnership with NVIDIA, dedicated to drug discovery and development. It is the most powerful AI factory wholly owned and operated by a pharmaceutical company, powered by 1,016 NVIDIA Blackwell Ultra GPUs and delivering more than 9,000 petaflops of AI performance.

Boehringer Ingelheim announced the expansion of its global Computational Innovation footprint with the launch of a new centre for AI and machine learning in London in April.

And Sanofi has invested C$294 million to expand its global Artificial Intelligence Centre of Excellence in Toronto, scaling AI across its research, manufacturing and business operations to develop and manufacture life-changing medicines and vaccines faster than ever before.

These are not pilot programmes. They are long-term capital commitments, to the idea that AI is now foundational to how drug discovery and development gets done.

What AI-driven science requires from the built environment

The physical demands of AI-intensive life sciences research are specific and often underestimated at briefing stage.

Power density requirements in AI-adjacent research environments are substantially higher than in conventional laboratory settings. Thermal management, vibration isolation, and the integration of computational infrastructure alongside wet lab operations all require careful engineering from the outset. The question of where wet lab work ends and compute-intensive work begins, and what that transition looks like in the building services, is one that needs to be answered in the design brief, not discovered during fit-out.

At Inuti, we are seeing these questions arrive earlier and earlier in project conversations. Our AI and quantum technology practice has direct experience designing and engineering precision research environments where the physical tolerances are unforgiving and the margin for misalignment between design intent and built reality is essentially zero.

Case study: Nu Quantum, Cambridge - a precision quantum computing research facility where extreme vibration isolation, electromagnetic shielding, and ultra-stable environmental control were integrated into the building design from the earliest stages. One of very few firms in the UK with direct experience in this type of environment.

Three trends, one conclusion

The Golden Triangle leasing data, the manufacturing investment cycle, and the scale of AI infrastructure commitment across biopharma are each significant on their own. Together, they point at the same thing: UK life sciences is entering a period of serious, sustained capital deployment, into research, into production, into the technology platforms that will define how medicines are discovered and made over the next decade.

That capital needs somewhere to go. The laboratories, manufacturing suites, and precision research environments being commissioned right now will be the physical infrastructure of that future. Getting them right, designed correctly from the outset, engineered to regulatory standard, delivered without the budget and timeline overruns that come from fragmented procurement, is what determines whether the ambition translates into operational reality.

We have been doing this work for over 60 years. Across Cambridge, London, Oxford and beyond. Across life sciences, pharmaceuticals, agri-tech, AI and quantum. For startups commissioning their first facility and for global pharmaceutical companies expanding their UK manufacturing footprint.

If you are planning a facility project, at any stage, we would welcome an early conversation.

Get in touch with the Inuti team →

Sources

1. Knight Frank Q1 2026 Golden Triangle data — knightfrank.co.uk

2. Cambridge Biomedical Campus land deal, Cambridgeshire County Council — cambridgeshire.gov.uk

3. London Cancer Hub expansion — cancerhub.london

4. LSIMF £600M investment announcement, Gov.uk (14 April 2026) — gov.uk

5. LillyPod launch, Eli Lilly — lilly.com

6. Boehringer Ingelheim AI accelerator, London — boehringer-ingelheim.com

7. Sanofi AI Centre of Excellence Toronto expansion (4 May 2026) — newswire.ca

Inuti is a global design and engineering firm delivering advanced facilities for science. With over 60 years of experience and 712,000+ sq ft delivered, we work with life sciences, pharmaceutical, agri-tech and technology companies at every stage of growth.

Get in touch